On Friday, Shares of Biogen Inc (NASDAQ:BIIB), lost -2.81% to $284.79.
Biogen and Swedish Orphan Biovitrum AB (publ) (Sobi) (SOBI.ST) received a positive recommendation from the European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) for the marketing authorisation of Elocta(TM) (rFVIIIFc). Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of haemophilia A that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the European Union (EU).
The positive opinion was based on results from the pivotal, phase 3 A-LONG clinical study, which examined the efficacy, safety and pharmacokinetics of rFVIIIFc in formerly treated males 12 years of age and older with severe haemophilia A, and from the phase 3 Kids A-LONG clinical study, which evaluated the efficacy and safety of rFVIIIFc in formerly treated male children with haemophilia A under 12 years of age. The Committee`s positive opinion is now referred to the European Commission (EC), which grants marketing authorisation for medicines in the EU.
“The CHMP`s recommendation to approve Elocta is an important milestone in potentially bringing this innovative therapeutic option to people with haemophilia A across Europe,” said Aoife Brennan, M.D, vice president of Hematology, Clinical Development at Biogen. “The potential of Elocta to provide protection against bleeding episodes with fewer prophylactic infusions will, if approved, represent the first treatment advance in nearly 20 years for Europe`s hemophilia community.”
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
Shares of Under Armour Inc (NYSE:UA), inclined 1.52% to $103.72, during its last trading session.
Regardless of age, nationality, or reputation, an unwavering persistence unites global football players all over the world. Recently Under Armour (UA) revealed its first global football campaign, “Slay Your Next Giant,” which will inform all future story telling and marketing efforts for the global football category and cements Under Armour as a brand that values the journey over the destination. “Giants” exist at every stage of the game, and to elevate their game footballers must overcome them.
Slay Your Next Giant was developed in partnership with Droga5, the creative agency behind other successful Under Armour campaigns counting I WILL WHAT I WANT featuring Misty Copeland and Gisele Bundchen and this summer’s RULE YOURSELF featuring Misty, Stephen Curry, Jordan Spieth and Tom Brady. The campaign’s digital story features Memphis Depay of Manchester United, Cameron Carter-Vickers of the Tottenham Hotspur Academy, in addition to young up-and-coming players from around the globe (Brazil, Chile, Mexico, and the UK), who are developing their talent on grass pitches, cement courts, and empty lots all over the world. Additional storylines feature Jermaine Jones of the MLS’ New England Revolution, Oswaldo Alanis and Jesus Corona of the Mexican National Team, and Gonzalo Fierro of Colo-Colo in Chile. Each player’s story is united by the final phrase “You’re just getting started,” which speaks to the ethos of the brand’s global football category as a whole.
Under Armour, Inc., together with its auxiliaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes.
At the end of Friday’s trade, Shares of Franklin Resources, Inc. (NYSE:BEN), gained 0.24% to $37.36.
The Templeton Russia and East European Fund, declared that the Fund’s Annual Meeting of Shareholders was adjourned until October 8, 2015, to permit further solicitation of proxies. The adjournment will give shareholders an additional opportunity to consider the matters being voted on and to exercise their voting rights. The Annual Meeting will be reconvened on October 8, 2015 at 12 Noon Eastern time at 300 S.E. 2nd Street, Fort Lauderdale, Florida.
The Fund’s investment manager, Templeton Asset Administration Ltd., is an indirect, wholly owned partner of Franklin Resources, Inc. (NYSE: BEN), a global investment administration organization operating as Franklin Templeton Investments. Franklin Templeton Investments provides global and domestic investment administration to retail, institutional and sovereign wealth clients in over 150 countries. Through specialized teams, the company has expertise across all asset classes — counting equity, fixed income, alternative and custom solutions. The company’s more than 600 investment professionals are supported by its integrated, worldwide team of risk administration professionals and global trading desk network. With offices in 35 countries, the California-based company has more than 65 years of investment experience and about $806 billion in assets under administration as of August 31, 2015. For more information, please visit franklintempleton.com.
Franklin Resources, Inc. is a publicly owned asset administration holding company. Through its auxiliaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships.
Finally, Cadence Design Systems Inc (NASDAQ:CDNS), ended its last trade with -0.45% loss, and closed at $20.95.
Cadence Design Systems, declared a broad intellectual property (IP) portfolio for TSMC’s 10nm FinFET (N10) process. Cadence has already secured multiple design wins with this portfolio and is actively engaged with customers as adoption of TSMC’s leading-edge process grows. The initial deliveries of Cadence IP for the N10 process demonstrate a 20 percent power reduction and 50 percent area reduction contrast to TSMC’s 16nm process technology, and are ideal for mobile and network infrastructure applications.
The Cadence IP portfolio for N10 comprises DDR4, USB 3.0, PCI Express® (PCIe®) 3.0, ADC, PLL and monitoring IP. For detailed product information and availability details, customers should contact their local Cadence salesperson.
“Together with TSMC, we provide innovations that lead to wider adoption of the newest technology nodes in the market,” said Hugh Durdan, vice president of marketing for Design IP at Cadence. “As a leading IP supplier, Cadence is well-positioned to enable customers working on 10nm designs to stay ahead of the competition by providing them early IP access to protocols most relevant to their markets.”
Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (design IP) for semiconductor and electronics systems industries worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
